Literature DB >> 2646225

CSF pharmacokinetics of ceftazidime in neurosurgical patients with an external ventriculostomy.

U Fuhr1, S Harder, S Häfner, D Rosenthal, R Lorenz, A H Staib.   

Abstract

In 11 neurosurgical patients (seven women, four men, aged 22-73 years) undergoing external ventriculostomy, serum and cerebrospinal fluid (CSF) pharmacokinetics of ceftazidime (CAZ) administered as a chemoprophylactic agent were evaluated. Concentrations of CAZ in CSF correlated significantly (p less than 0.05) with serum concentrations and with leucocyte counts in CSF. Peak concentrations in CSF (range 0-25.5 mg/l) exceeded the MIC90 of Staphylococcus species in two and of Pseudomonas and Enterobacter species in five of 11 patients. The MIC90 values of the other relevant bacteria causing CNS infections in these patients were surpassed in nine of 11 patients.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2646225     DOI： 10.1007/bf01643492

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  12 in total

1.  Infections complicating the use of external ventriculostomy.

Authors:  R W Smith; J F Alksne
Journal:  J Neurosurg       Date:  1976-05       Impact factor: 5.115

Review 2.  Antimicrobial prophylaxis in surgery.

Authors:  A B Kaiser
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

3.  Gram-negative bacillary meningitis.

Authors:  J L LeFrock; B R Smith; A Molavi
Journal:  Med Clin North Am       Date:  1985-03       Impact factor: 5.456

4.  Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation.

Authors:  I W Fong; K B Tomkins
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis.

Authors:  J Modai; D Vittecoq; J M Decazes; M Wolff; A Meulemans
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

6.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

Authors:  R A Walstad; K B Hellum; S Blika; L G Dale; T Fredriksen; K I Myhre; G R Spencer
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

Review 7.  Bacterial infections of the central nervous system in neurosurgery.

Authors:  J H Tenney
Journal:  Neurol Clin       Date:  1986-02       Impact factor: 3.806

8.  Ventriculostomy-related infections. A prospective epidemiologic study.

Authors:  C G Mayhall; N H Archer; V A Lamb; A C Spadora; J W Baggett; J D Ward; R K Narayan
Journal:  N Engl J Med       Date:  1984-03-01       Impact factor: 91.245

9.  The in-vitro activity of ceftazidime against clinically important pathogens.

Authors:  H Knothe; G A Dette
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

10.  The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates.

Authors:  S M Harding; P B Harper
Journal:  Infection       Date:  1983       Impact factor: 3.553
View more
  2 in total

1.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 2.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.